NOT YET RECRUITING: NTI164 Rett syndrome trial – Australia
Posted: Thu Sep 03, 2026 10:48 pm
Status: Not yet recruitingStudy: Efficacy and safety of NTI164 in children and young adults with Rett syndrome
Registry number: NCT07257978
Country: Australia
Participants: Females aged 4–25 years
What is being studied?
This planned study will evaluate the safety and possible effectiveness of NTI164, a full-spectrum medicinal cannabis plant extract containing a low concentration of THC, in Rett syndrome. The registry lists Monash Children’s Clinical Trial Centre as the contact.
Contact: +61 3 9594 6666 — MonashChildrensCTC@monashhealth.org
Official study record: https://clinicaltrials.gov/study/NCT07257978
Information checked 3 September 2026. Recruitment had not started at the time of checking. Medicinal cannabis can interact with medicines and should only be considered through the study team and the person’s clinician.
Registry number: NCT07257978
Country: Australia
Participants: Females aged 4–25 years
What is being studied?
This planned study will evaluate the safety and possible effectiveness of NTI164, a full-spectrum medicinal cannabis plant extract containing a low concentration of THC, in Rett syndrome. The registry lists Monash Children’s Clinical Trial Centre as the contact.
Contact: +61 3 9594 6666 — MonashChildrensCTC@monashhealth.org
Official study record: https://clinicaltrials.gov/study/NCT07257978
Information checked 3 September 2026. Recruitment had not started at the time of checking. Medicinal cannabis can interact with medicines and should only be considered through the study team and the person’s clinician.